HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE

The present invention relates generally to methods for treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF) comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp, or the functional analogue thereof, to form a complex with, and thereby neutralise, the cell-free Hb. Aspects of the invention further relate to compositions and kits of an artificial CSF comprising Hp. 本发明一般涉及治疗或预防伴随血管外红细胞溶解和无细胞血红蛋白(Hb)释放进入脑脊液(CSF)的出血性中风后受试者的不良继发性神经学后果的方法，包括使有此需要的受试者CSF暴露于治疗有效量的触珠蛋白(Hp)并持续足以允许Hp或其功能类似物与无细胞Hb形成复合物的时间段，且由此中和无细胞Hb。本发明的方面还涉及包含Hp的人工CSF的组合物和试剂盒。